BioSpace News Archive

- Potential to be First Superior Therapy to Standard of Care for Chemotherapy-Induced Neutropenia in 30 Years - - Targeting CIN After All Chemotherapies in All Cancer Types in Combination with All G-CSFs - - Strong Patent Protection Through 2036 - NEW YORK, March 30, 2020 (GLOBE NEWSWIRE) -- BeyondSpring Inc. (the “Company” or “BeyondSpring”) (NASDAQ: BYSI), a global biopharmaceutical company headquartered in New York focused on the development of innovative immuno-oncolog

Bellerophon Therapeutics, Inc. (Nasdaq: BLPH), a clinical-stage biotherapeutics company focused on developing treatments for cardiopulmonary diseases, today announced that expanded access treatment with the INOpulse® inhaled nitric oxide system (iNO) was initiated for the first time in a patient with a diagnosis of the novel coronavirus disease (COVID-19) at the University of Miami School of Medicine. The treatment follows the recent decision by

Cronos Group Inc. (NASDAQ: CRON) (TSX: CRON) (“Cronos Group” or the “Company”) will report its 2019 Fourth Quarter and Full-Year Financial Results on Monday, March 30, 2020 after the close of trading on NASDAQ.

The device is designed to restore vision to persons blinded by age-related macular degeneration and retinitis pigmentosa

Agilent Technologies Inc. (NYSE: A) today introduced the Agilent K6460S Clinical Edition TQ LC/MS system, designed to improve in vitro diagnostic workflows in clinical labs.

Article reviews mechanisms of action (MOA) of medications used in the treatment of patients with narcolepsy and clinical implications

Aptorum Group Limited (NASDAQ:APM) (“Aptorum Group”), a biopharmaceutical company focused on the development of novel therapeutics to address global unmet medical needs, today announced that Ian Huen, Chief Executive Officer and Executive Director, and Darren Lui, President and Executive Director, will present at the Solebury Trout Virtual Investor Conference on Thursday, April 2, at 12:00 pm ET

Nemaura Medical Inc. (NASDAQ: NMRD) (“Nemaura” or the “Company”), a medical technology company focused on developing micro-systems-based wearable diagnostic devices and digital solutions for the medical and consumer markets, announced it is planning to launch a digital healthcare subscription service in the USA under the brand name proBEAT™.

CohBar, Inc. (NASDAQ: CWBR), a clinical stage biotechnology company developing mitochondria based therapeutics to treat chronic diseases and extend healthy lifespan, today announced that it is anticipating delays in the completion of its CB4211 Phase 1b study for NASH and obesity. This delay is a result of a pause by some of the company’s clinical research organization partners in all of their activities related to the study in response t

GenoFAB Inc. recently announced it would partner with Decisions LLC to help accelerate biomedical research projects